{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:49:41Z","timestamp":1766180981198,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004\u20132013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22\u20130.63) for those without cirrhosis and 0.54 (0.31\u20130.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and \u03b1-fetoprotein levels were associated with HCC (p\u2009&lt;\u20090.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored.<\/jats:p>","DOI":"10.1038\/s41598-017-02313-y","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T11:32:36Z","timestamp":1497267156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients"],"prefix":"10.1038","volume":"7","author":[{"given":"Mei-Hsuan","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Chou","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-3190","authenticated-orcid":false,"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8082-7144","authenticated-orcid":false,"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Pang","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwong-Ming","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Heng","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Jer","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-I","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Ta","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwai-I","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Shyan","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,16]]},"reference":[{"key":"2313_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology \n                           57, 1333\u20131342, doi:10.1002\/hep.26141 (2013).","journal-title":"Hepatology"},{"key":"2313_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/apt.12300","volume":"37","author":"LH Nguyen","year":"2013","unstructured":"Nguyen, L. H. & Nguyen, M. H. Systematic review: Asian patients with chronic hepatitis C infection. Alimentary pharmacology & therapeutics \n                           37, 921\u2013936, doi:10.1111\/apt.12300 (2013).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"2313_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. & Bell, B. P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol \n                           45, 529\u2013538, doi:10.1016\/j.jhep.2006.05.013 (2006).","journal-title":"J Hepatol"},{"key":"2313_CR4","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1200\/JCO.2010.29.1500","volume":"28","author":"MH Lee","year":"2010","unstructured":"Lee, M. H. et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol \n                           28, 4587\u20134593, doi:JCO.2010.29.1500 (2010).","journal-title":"J Clin Oncol"},{"key":"2313_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee, M. H. et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis \n                           206, 469\u2013477, doi:10.1093\/infdis\/jis385 (2012).","journal-title":"J Infect Dis"},{"key":"2313_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli, A., Shaffer, A., Sherman, A. & Kottilil, S. Treatment of hepatitis C: A systematic review. JAMA \n                           312, 631\u2013640, doi:10.1001\/jama.2014.7085 (2014).","journal-title":"JAMA"},{"key":"2313_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","volume":"115","author":"JH Kao","year":"2016","unstructured":"Kao, J. H. Hepatitis C virus infection in Taiwan: Past, present, and future. J Formos Med Assoc \n                           115, 65\u201366, doi:10.1016\/j.jfma.2015.06.012 (2016).","journal-title":"J Formos Med Assoc"},{"key":"2313_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature \n                           461, 399\u2013401, doi:10.1038\/nature08309 (2009).","journal-title":"Nature"},{"key":"2313_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrgastro.2013.143","volume":"11","author":"S Singh","year":"2014","unstructured":"Singh, S., Singh, P. P., Roberts, L. R. & Sanchez, W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol \n                           11, 45\u201354, doi:10.1038\/nrgastro.2013.143 (2014).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2313_CR10","doi-asserted-by":"publisher","first-page":"e001313","DOI":"10.1136\/bmjopen-2012-001313","volume":"2","author":"N Kimer","year":"2012","unstructured":"Kimer, N., Dahl, E. K., Gluud, L. L. & Krag, A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ open \n                           2, e001313, doi:10.1136\/bmjopen-2012-001313 (2012).","journal-title":"BMJ open"},{"key":"2313_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(00)03595-9","volume":"357","author":"S Nishiguchi","year":"2001","unstructured":"Nishiguchi, S. et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet \n                           357, 196\u2013197, doi:10.1016\/S0140-6736(00)03595-9 (2001).","journal-title":"Lancet"},{"key":"2313_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida, H. et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med \n                           131, 174\u2013181, doi:10.7326\/0003-4819-131-3-199908030-00003 (1999).","journal-title":"Ann Intern Med"},{"key":"2313_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0140-6736(95)91739-X","volume":"346","author":"S Nishiguchi","year":"1995","unstructured":"Nishiguchi, S. et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet \n                           346, 1051\u20131055, doi:10.1016\/S0140-6736(95)91739-X (1995).","journal-title":"Lancet"},{"key":"2313_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.23744","volume":"52","author":"TR Morgan","year":"2010","unstructured":"Morgan, T. R. et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology \n                           52, 833\u2013844, doi:10.1002\/hep.23744 (2010).","journal-title":"Hepatology"},{"key":"2313_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","volume":"9","author":"LI Backus","year":"2011","unstructured":"Backus, L. I. et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol \n                           9, 509\u2013516 e501, doi:10.1016\/j.cgh.2011.03.004 (2011).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2313_CR16","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA \n                           308, 2584\u20132593, doi:10.1001\/jama.2012.144878 (2012).","journal-title":"JAMA"},{"key":"2313_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","volume":"58","author":"E Ogawa","year":"2013","unstructured":"Ogawa, E. et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol \n                           58, 495\u2013501, doi:10.1016\/j.jhep.2012.10.017 (2013).","journal-title":"J Hepatol"},{"key":"2313_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan, R. L. et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med \n                           158, 329\u2013337, doi:10.7326\/0003-4819-158-5-201303050-00005 (2013).","journal-title":"Ann Intern Med"},{"key":"2313_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/cid\/cit234","volume":"57","author":"S Aleman","year":"2013","unstructured":"Aleman, S. et al. A risk for hepatocellular carcinoma still persists long-term after sustained virological response in patients with hepatitis C associated liver cirrhosis. Clin Infect Dis \n                           57, 230\u2013236, doi:10.1093\/cid\/cit234 (2013).","journal-title":"Clin Infect Dis"},{"key":"2313_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard, A. et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology \n                           46, 32\u201336, doi:10.1002\/hep.21669 (2007).","journal-title":"Hepatology"},{"key":"2313_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix, J. & Sherman, M. American Association for the Study of Liver, D. Management of hepatocellular carcinoma: an update. Hepatology \n                           53, 1020\u20131022, doi:10.1002\/hep.24199 (2011).","journal-title":"Hepatology"},{"key":"2313_CR22","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/hep.27630","volume":"61","author":"CJ Chiang","year":"2015","unstructured":"Chiang, C. J. et al. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology \n                           61, 1154\u20131162, doi:10.1002\/hep.27630 (2015).","journal-title":"Hepatology"},{"key":"2313_CR23","doi-asserted-by":"publisher","first-page":"e70458","DOI":"10.1371\/journal.pone.0070458","volume":"8","author":"CS Hsu","year":"2013","unstructured":"Hsu, C. S. et al. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS One \n                           8, e70458, doi:10.1371\/journal.pone.0070458 (2013).","journal-title":"PLoS One"},{"key":"2313_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.28535","volume":"64","author":"HB El-Serag","year":"2016","unstructured":"El-Serag, H. B., Kanwal, F., Richardson, P. & Kramer, J. Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection. Hepatology \n                           64, 130\u20137, doi:10.1002\/hep.28535 (2016).","journal-title":"Hepatology"},{"key":"2313_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh, B., Grebely, J. & Dore, G. J. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol \n                           10, 553\u2013562, doi:10.1038\/nrgastro.2013.107 (2013).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2313_CR26","doi-asserted-by":"publisher","first-page":"e4311","DOI":"10.1097\/MD.0000000000004311","volume":"95","author":"N Coppola","year":"2016","unstructured":"Coppola, N., Onorato, L., Sagnelli, C., Sagnelli, E. & Angelillo, I. F. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine \n                           95, e4311, doi:10.1097\/md.0000000000004311 (2016).","journal-title":"Medicine"},{"key":"2313_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/0003-4819-146-9-200705010-00008","volume":"146","author":"K Ikeda","year":"2007","unstructured":"Ikeda, K., Marusawa, H. & Osaki, Y. et al. Antibody to hepatitis b core antigen and risk for hepatitis c\u2013related hepatocellular carcinoma: A prospective study. Annals of Internal Medicine \n                           146, 649\u2013656, doi:10.7326\/0003-4819-146-9-200705010-00008 (2007).","journal-title":"Annals of Internal Medicine"},{"key":"2313_CR28","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/1078-0432.CCR-16-0921","volume":"23","author":"ML Yu","year":"2016","unstructured":"Yu, M. L. et al. Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatic C virus patients: a model for prioritization of treatment. Clin Cancer Res \n                           23, 1690\u20131697, doi:10.1158\/1078-0432.CCR-16-0921 (2016).","journal-title":"Clin Cancer Res"},{"key":"2313_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7326\/0003-4819-139-1-200307010-00012","volume":"139","author":"S Gupta","year":"2003","unstructured":"Gupta, S., Bent, S. & Kohlwes, J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med \n                           139, 46\u201350, doi:10.7326\/0003-4819-139-1-200307010-00012 (2003).","journal-title":"Ann Intern Med"},{"key":"2313_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00004836-200103000-00014","volume":"32","author":"CW Chu","year":"2001","unstructured":"Chu, C. W. et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol \n                           32, 240\u2013244, doi:10.1097\/00004836-200103000-00014 (2001).","journal-title":"J Clin Gastroenterol"},{"key":"2313_CR31","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1111\/j.1572-0241.1998.00703.x","volume":"93","author":"N Bayati","year":"1998","unstructured":"Bayati, N., Silverman, A. L. & Gordon, S. C. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol \n                           93, 2452\u20132456, doi:10.1111\/j.1572-0241.1998.00703.x (1998).","journal-title":"Am J Gastroenterol"},{"key":"2313_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1572-0241.2004.04152.x","volume":"99","author":"KQ Hu","year":"2004","unstructured":"Hu, K. Q. et al. Clinical Significance of Elevated Alpha-Fetoprotein (AFP) in Patients with Chronic Hepatitis C, but not Hepatocellular Carcinoma. Am J Gastroenterol \n                           99, 860\u2013865, doi:10.1111\/j.1572-0241.2004.04152.x (2004).","journal-title":"Am J Gastroenterol"},{"key":"2313_CR33","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1440-1746.2007.04898.x","volume":"22","author":"TM Chen","year":"2007","unstructured":"Chen, T. M. et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. Journal of gastroenterology and hepatology \n                           22, 669\u2013675, doi:10.1111\/j.1440-1746.2007.04898.x (2007).","journal-title":"Journal of gastroenterology and hepatology"},{"key":"2313_CR34","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.26442","volume":"58","author":"Y Asahina","year":"2013","unstructured":"Asahina, Y. et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology \n                           58, 1253\u20131262, doi:10.1002\/hep.26442 (2013).","journal-title":"Hepatology"},{"key":"2313_CR35","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/jgh.13236","volume":"31","author":"Y Nagaoki","year":"2016","unstructured":"Nagaoki, Y. et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. Journal of gastroenterology and hepatology \n                           31, 1009\u20131015, doi:10.1111\/jgh.13236 (2016).","journal-title":"Journal of gastroenterology and hepatology"},{"key":"2313_CR36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/hep.27305","volume":"60","author":"K Yamasaki","year":"2014","unstructured":"Yamasaki, K. et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology \n                           60, 1563\u20131570, doi:10.1002\/hep.27305 (2014).","journal-title":"Hepatology"},{"key":"2313_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jhep.2014.02.022","volume":"61","author":"CF Huang","year":"2014","unstructured":"Huang, C. F. et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol \n                           61, 67\u201374, doi:10.1016\/j.jhep.2014.02.022 (2014).","journal-title":"J Hepatol"},{"key":"2313_CR38","doi-asserted-by":"publisher","first-page":"e18322","DOI":"10.1371\/journal.pone.0018322","volume":"6","author":"CY Lin","year":"2011","unstructured":"Lin, C. Y. et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One \n                           6, e18322, doi:10.1371\/journal.pone.0018322 (2011).","journal-title":"PLoS One"},{"key":"2313_CR39","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/hep.22319","volume":"47","author":"ML Yu","year":"2008","unstructured":"Yu, M. L. et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology \n                           47, 1884\u20131893, doi:10.1002\/hep.22319 (2008).","journal-title":"Hepatology"},{"key":"2313_CR40","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1086\/592579","volume":"47","author":"CH Liu","year":"2008","unstructured":"Liu, C. H. et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis \n                           47, 1260\u20131269, doi:10.1086\/592579 (2008).","journal-title":"Clin Infect Dis"},{"key":"2313_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hep.23976","volume":"53","author":"ML Yu","year":"2011","unstructured":"Yu, M. L. et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology \n                           53, 7\u201313, doi:10.1002\/hep.23976 (2011).","journal-title":"Hepatology"},{"key":"2313_CR42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","volume":"64","author":"CH Liu","year":"2015","unstructured":"Liu, C. H. et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut \n                           64, 303\u2013311, doi:10.1136\/gutjnl-2014-307080 (2015).","journal-title":"Gut"},{"key":"2313_CR43","doi-asserted-by":"publisher","first-page":"17030","DOI":"10.1038\/srep17030","volume":"5","author":"MH Lee","year":"2015","unstructured":"Lee, M. H. et al. Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep \n                           5, 17030, doi:10.1038\/srep17030 (2015).","journal-title":"Sci Rep"},{"key":"2313_CR44","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature genetics \n                           41, 1105\u20131109, doi:10.1038\/ng.449 (2009).","journal-title":"Nature genetics"},{"key":"2313_CR45","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature \n                           461, 798\u2013801, doi:10.1038\/nature08463 (2009).","journal-title":"Nature"},{"key":"2313_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/liv.13194","volume":"37","author":"YJ Lin","year":"2016","unstructured":"Lin, Y. J. et al. Chronic Hepatitis C Virus Infection and the Risk for Diabetes: A Community-Based Prospective Study. Liver International \n                           37, 179\u2013186, doi:10.1111\/liv.13194 (2016).","journal-title":"Liver International"},{"key":"2313_CR47","doi-asserted-by":"crossref","unstructured":"Lee, M. H. et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke \n                           41, 2894\u20132900, doi:STROKEAHA.110.598136 (2010).","DOI":"10.1161\/STROKEAHA.110.598136"},{"key":"2313_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/hep.28387","volume":"63","author":"TH Su","year":"2016","unstructured":"Su, T. H. et al. Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. Hepatology \n                           63, 721\u2013730, doi:10.1002\/hep.28387 (2016).","journal-title":"Hepatology"},{"key":"2313_CR49","doi-asserted-by":"publisher","first-page":"e0126031","DOI":"10.1371\/journal.pone.0126031","volume":"10","author":"YH Kuo","year":"2015","unstructured":"Kuo, Y. H. et al. Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care. PLoS One \n                           10, e0126031, doi:10.1371\/journal.pone.0126031 (2015).","journal-title":"PLoS One"},{"key":"2313_CR50","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1097\/MD.0000000000000690","volume":"94","author":"ML Yu","year":"2015","unstructured":"Yu, M. L. et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore) \n                           94, e690, doi:10.1097\/MD.0000000000000690 (2015).","journal-title":"Medicine (Baltimore)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02313-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02313-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02313-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T05:27:27Z","timestamp":1671773247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02313-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,16]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["2313"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-02313-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2017,6,16]]},"assertion":[{"value":"12 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3718"}}